| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 1250% | ₹1,100 0% | 4,500 | - | - |
| - | - | 4,700 | ₹14.95 -12.05% | 7,0005500% |
| - | - | 4,800 | ₹22 -9.46% | 10,125305% |
| - | - | 4,850 | ₹25.7 -19.68% | 2,1256.25% |
| - | - | 4,900 | ₹31.5 -12.5% | 5,125272.72% |
| - | - | 4,950 | ₹39 -3.46% | 3,3753.84% |
| 6250% | ₹446 0% | 5,000 | ₹45.7 1.78% | 19,87547.22% |
| - | - | 5,050 | ₹63.2 -1.86% | 3750% |
| - | - | 5,100 | ₹64.7 -7.57% | 8,62586.48% |
| - | - | 5,150 | ₹59.2 0% | 5000% |
| - | - | 5,200 | ₹91.5 0.16% | 6,12548.48% |
| - | - | 5,250 | ₹107.4 -0.09% | 1,250400% |
| 3750% | ₹259.65 0% | 5,300 | ₹125.7 -2.33% | 21,625458.06% |
| 9,25094.73% | ₹234 11.42% | 5,350 | ₹146.3 -8.56% | 13,12510400% |
| 24,62598.98% | ₹205.25 7.34% | 5,400 | ₹169.6 -0.11% | 59,250190.79% |
| 10,875222.22% | ₹181.3 4.19% | 5,450 | ₹194.5 -21.06% | 2,750340% |
| 44,375234.90% | ₹159 7.14% | 5,500 | ₹221.3 9.28% | 37,50040.18% |
| 37550% | ₹141.15 -34.44% | 5,550 | - | - |
| 18,00054.83% | ₹125.9 11.71% | 5,600 | ₹289.1 0% | 1,0000% |
| 1,7501300% | ₹104.3 -16.56% | 5,650 | - | - |
| 11,000193.33% | ₹92.2 13.82% | 5,700 | ₹362.15 0% | 3750% |
| 1,750600% | ₹67.15 -28.56% | 5,800 | ₹371.1 0% | 2500% |
| 31,250331.03% | ₹49.65 16.14% | 5,900 | - | - |
| 1,2500% | ₹77.05 0% | 5,950 | - | - |
| 78,37572.25% | ₹36.8 10.17% | 6,000 | - | - |
| 4,125266.66% | ₹30.7 3.54% | 6,050 | - | - |
| 3750% | ₹54.35 0% | 6,100 | - | - |
| 2500% | ₹45.25 0% | 6,150 | - | - |
| 12,125273.07% | ₹18.55 154.1% | 6,200 | ₹760.4 0% | 00% |
| 1250% | ₹29.5 0% | 6,300 | - | - |
| 1,750180% | ₹10.4 -30.66% | 6,400 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
